Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

23.57 -1.53 (-6.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 838,960
Open 25.10
Bid (Size) 23.21 (2)
Ask (Size) 24.00 (1)
Prev. Close 25.10
Today's Range 23.51 - 25.20
52wk Range 20.67 - 39.83
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran. 
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga

Performance

YTD
-23.98%
-23.98%
1 Month
-5.02%
-5.02%
3 Month
-15.11%
-15.11%
6 Month
-21.42%
-21.42%
1 Year
-34.09%
-34.09%

More News

Read More
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
Via InvestorPlace
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024
Via InvestorPlace
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Via Benzinga
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
Via InvestorPlace
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
Via Benzinga
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Via InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.